Ischemic heart diseases: current treatments and future.
Ischemic heart disease is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Conventional surgery-based therapy for the treatment of ischemic heart diseases has been advanced with biopharmaceutical-based therapy, such as protein, gene and cell therapy. The conventional medical therapy focuses on the use of drug eluting stents, coronary-artery bypass-graft surgery and anti-thrombosis. Biopharmaceutical-based therapies including recombinant protein therapy, gene therapy and cell transplantation are recognized as promising approaches in inducing neovascularization and improving collateral blood flow in the ischemic heart. This review explores the current status and future of the treatment of ischemic heart diseases with conventional medical therapy, biopharmaceutical-based therapy focused on the proteins and polymeric hydrogels for delivery of therapeutic proteins.
Choi
Donghoon
D
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei Cardiovascular Research Institute, Yonsei University, College of Medicine, Seoul, 120-749, Republic of Korea.
Hwang
Ki-Chul
KC
Lee
Kuen-Yong
KY
Kim
Yong-Hee
YH
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D001026:Coronary Artery Bypass; D016503:Drug Delivery Systems; D005079:Excipients; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D020100:Hydrogels; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D005079:Excipients; D005343:Fibrinolytic Agents; D020100:Hydrogels; D011506:Proteins